https://www.carnivalcorp.com/news-releases/news-release-details/aida-cruises-announces-expansion-its-selection-program
G1 Therapeutics Announces Initiation Of New Phase 2 Trial Of Trilaciclib In Combination With The Antibody-Drug Conjugate, Trodelvy
G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib administered prior to the antibody-drug
